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Abstract
Anti-malarial drugs can make a significant contribution to the control of malaria in endemic areas when used for
prevention as well as for treatment. Chemoprophylaxis is effective in preventing deaths and morbidity from
malaria, but it is difficult to sustain for prolonged periods, may interfere with the development of naturally
acquired immunity and will facilitate the emergence and spread of drug resistant strains if applied to a whole
community. However, chemoprophylaxis targeted to groups at high risk, such as pregnant women, or to periods
of the year when the risk from malaria is greatest, can be an effective and cost effective malaria control tool and
has fewer drawbacks. Intermittent preventive treatment, which involves administration of anti-malarials at fixed
time points, usually when a subject is already in contact with the health services, for example attendance at an
antenatal or vaccination clinic, is less demanding of resources than chemoprophylaxis and is now recommended
for the prevention of malaria in pregnant women and infants resident in areas with medium or high levels of
malaria transmission. Intermittent preventive treatment in older children, probably equivalent to targeted
chemoprophylaxis, is also highly effective but requires the establishment of a specific delivery system. Recent stu-
dies have shown that community volunteers can effectively fill this role. Mass drug administration probably has lit-
tle role to play in control of mortality and morbidity from malaria but may have an important role in the final
stages of an elimination campaign.
Background
This review on the use of anti-malarial drugs to prevent
malaria in the population of malaria endemic areas
focuses on Africa where the potential for this approach
to malaria control is greatest. Some of the issues
reviewed here are relevant to other high transmission
areas, such as Papua New Guinea and a few parts of
South East Asia but, in general, diagnosis and treatment
is a more relevant malaria control strategy in the low to
medium transmission areas of Asia and South America
than chemoprevention.
Anti-malarial drugs can be used to prevent malaria in a
number of different ways (Table 1). However, there is con-
siderable overlap between these different approaches
(Figure 1) [1]. For example, it is now clear that the major
mode of action of Intermittent Preventive Treatment (IPT)
in infants (IPTi) and in children (IPTc) is prophylaxis, so
that this intervention overlaps with approaches previously
termed seasonal or targeted chemoprophylaxis. Further-
more, several mass drug administration (MDA) pro-
grammes have involved administration of several rounds of
treatment and this approach, therefore, overlaps with IPT.
Chemoprophylaxis
Anti-malarial drugs have been used to prevent malaria
in travellers to malaria endemic areas for hundreds of
years and the use of prophylactic quinine was one of the
key features that enabled Europeans to colonize the
highly endemic regions of West and Central Africa.
Without quinine, death from malaria was almost inevita-
ble. More recently, chemoprophylaxis has been used to
protect effectively the millions of tourists who visit
malaria endemic areas each year for business or holi-
days. In view of the efficacy of chemoprophylaxis in
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protecting non-immunes, it is surprising that so little
attention has been given to the use of drugs to protect
the local population. If prophylaxis can be used effec-
tively to protect an expatriate and his family for decades
why should the same approach not be used to protect at
risk groups in the local population?
Because of the increased risk of malaria in pregnancy,
chemoprophylaxis with pyrimethamine or chloroquine
[CQ] was used quite widely in some parts of Africa in
the 1950s and 1960s and, for a while, chemoprophylaxis
with CQ was a WHO recommended policy for the pre-
vention of malaria in pregnancy. Chemoprophylaxis with
an effective drug reduced maternal anaemia and low
birth weight [2], but prophylaxis with CQ fell into dis-
use because of side effects and increasing resistance to
this drug. It was not appreciated at this time that anti-
malarials continue to be effective in preventing malaria
after resistance has increased to a degree when they are
no longer effective for treatment of clinical malaria in
children, the group in whom drug sensitivity is usually
measured [3].
Only a relatively small number of trials of chemopro-
phylaxis have been undertaken in children living in
endemic areas but these have shown convincingly that
chemoprophylaxis with an effective drug decreases
deaths from malaria, prevents uncomplicated attacks of
malaria, reduces the prevalence of anaemia and
improves school attendance [4]. Despite these impress-
ive results, chemoprophylaxis in children has rarely been
deployed on a large scale in malaria endemic popula-
tions. A few, large commercial concerns have used che-
moprophylaxis to protect their work force and their
families from malaria and, for a while, a small number
of countries, such as Senegal, implemented widespread
prophylaxis with CQ in children during the malaria
transmission season but this was not sustained.
Table 1 Definitions of different forms of chemoprevention
a. Chemoprophylaxis. This term is used to describe the administration of an antimalarial drug or drug combination in such a way that blood levels
are maintained above the inhibitory level of survival of the local strains of parasite for the whole of the period at risk and, in the case of travellers,
for an appropriate period afterwards in order to kill emerging liver forms.
b. Intermittent preventive treatment (IPT). This term is used to describe the administration of a full curative dose of an antimalarial or antimalarial
combination to a selected, target population at specified times without determining whether or not the subject is infected. It is recognized that
between drug administrations blood levels may fall below the protective level and that infections may still occur although some of these may be
truncated by persistent low levels of drug.
c. Mass drug administration (MDA). This term is used to describe the administration of an antimalarial drug or drug combination to a whole
population without screening for the presence of infection. MDA may involve either the administration of a full therapeutic course or a sub-
therapeutic one as once practized through the use of medicated salt.
Figure 1 Overlap in the different forms of chemoprevention. Adapted from reference [2].
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In view of the results of carefully conducted trials that
have demonstrated the efficacy of chemoprophylaxis in
preventing mortality and morbidity from malaria in Afri-
can children why have countries in Africa not adopted
this highly effective control measure? There are number
of reasons why this has been the case, some of which
have more foundation than others. These include -
a. Cost. Purchasing and delivering prophylactic drugs
to the whole population indefinitely would be costly and
so this approach has never been seriously entertained.
Instead a focus has been placed on high-risk groups
such as pregnant women and young children. Economic
evaluation has shown that chemoprophylaxis with a
relatively inexpensive drug targeted at pregnant women
or children is cost effective [5].
b. Sustainability. Sustainability is a challenge for any
long-term preventive programme. Several malaria che-
moprophylaxis programmes, for example a large pro-
gramme in Sierra Leone, started well but tailed off due
to lack of enthusiasm on the part of the deliverers and
the recipients. However, this is not inevitable and deliv-
ery of anti-malarials for prevention can be sustained
over many years, even when unpaid volunteers are used
[6]. Sustainability is being achieved in several mass drug
administration programmes such as those being used to
control onchocerciasis, filariasis and intestinal
helminths.
c. Acceptability. The bitter taste of CQ and its propen-
sity to cause itching contributed to the poor uptake of
CQ prophylaxis in pregnancy with both pregnant
women being reluctant to take the drug on a regular
basis and health workers reluctant to provide it. Pyri-
methamine was better accepted but is no longer effica-
cious. Any drug used for prophylaxis in large
populations must be well tolerated as well as safe and
few anti-malarials meet both of these criteria.
d. Drug resistance. Widespread use of drugs for pre-
vention, especially if used in an uncoordinated way, will
inevitably increase drug pressure and facilitate the
spread of resistant parasites. However, targeting chemo-
prophylaxis to at risk groups, thus reducing the overall
number of parasites in a community exposed to the
drug, reduces this risk.
e. Loss of immunity. There is some evidence that
provision of prophylaxis to young children, in particu-
lar to infants, impairs the development of natural
immunity and thus increase their susceptibility to
malaria when the intervention is stopped [7,8]. How-
ever, this is not a problem specific to chemoprevention
as this constraint applies to any effective anti-malarial
intervention, for example vector control, which is not
sustained. However, stopping a sustained period of
chemoprevention may pose a greater risk than failing
to replace an insecticide treated bed net (ITN) or to
continue with indoor residual spraying [IRS] as the
transition from protected to unprotected status will
occur more rapidly.
Some of the challenges to the use of chemoprophy-
laxis in the population of endemic countries are soluble.
For example, restricting chemoprophylaxis to groups
most at risk and/or to the periods of the year when the
risk of malaria is highest reduces drug pressure and
costs and enhances the chances of sustainability. Devel-
opment of new, well-tolerated anti-malarials which pro-
vide a long period of protection, ideally several months,
would reduce the problems of delivery and compliance
and might reduce cost even further.
Intermittent preventive treatment
Intermittent preventive treatment (IPT), probably an
inappropriate name as it appears that much of the
impact of IPT is achieved through prophylaxis, involves
giving a full curative dose of an anti-malarial or anti-
malarial combination at fixed times regardless of
whether or not a subject is known to be infected. IPT
differs from chemoprophylaxis in that drug levels are
allowed to fall below protective levels between treat-
ments. Thus, IPT would be expected to be less effica-
cious than chemoprophylaxis but to have less of a
deleterious effect on the development of naturally
acquired immunity, by allowing occasional exposure to
parasites, and to exert less drug pressure. IPT was inves-
tigated initially as a means of controlling malaria in
pregnancy but it has subsequently been extended to the
prevention of malaria in infants, young children and
school children.
Pregnancy
IPT with a single dose of sulphadoxine/pyrimethamine
(SP) was introduced as an approach to the control of
malaria in pregnancy because of the unpopularity of CQ
chemoprophylaxis and increasing CQ resistance. Early
studies showed that IPT, given two or three times dur-
ing the second and third trimesters of pregnancy, was at
least as effective at preventing maternal anaemia and
low birth weight as chemoprophylaxis with CQ and
much more acceptable [3]. Thus, IPT with SP is recom-
mended by WHO for all pregnant women resident in
areas with a moderate or high level of malaria transmis-
sion [9]. How IPT in pregnancy (IPTp) with SP achieves
its impact is still not fully understood. SP provides 4- 6
weeks prophylaxis against sensitive isolates and thus, if
given as recommended on two or three occasions during
the second and third trimesters, it will provide prophy-
laxis for only about half of this period; a longer acting
drug would be expected to be more effective. However,
a single dose of SP should be able to clear any parasites
sequestering in the placenta, which are acquired during
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the periods when drug levels are too low to provide
protection.
Many countries in Africa have scaled up delivery of
IPTp with SP substantially, approaching the targets set
by the Roll Back Malaria Partnership and WHO. How-
ever, IPTp with SP as a malaria control strategy is now
challenged from two directions – SP resistance and a
decreasing burden of malaria in many, previously highly
endemic countries. The ability of an anti-malarial drug
to prevent malaria in the face of increasing drug resis-
tance may persist longer than its ability to cure clinical
infections [3], but a point will be reached when it can
do neither and this point has now been reached in
many parts of the malaria endemic world. Which anti-
malarial could be used to replace SP? Mefloquine has
some of the desirable characteristics, providing a long
period of prophylaxis and trials of IPTp with mefloquine
conducted in Malawi [10] and Benin [11] have shown
that it is effective but side effects are a problem when
the drug is used in this way. The combination of SP
with amodiaquine (AQ) was also effective, but AQ was
not well tolerated [12]. Other combinations being
explored are azithromycin combined with SP or CQ
[13]. Although azithromycin is a relatively ineffective
anti-malarial it is an effective treatment for several sexu-
ally transmitted diseases, some of which can cause low
birth weight. This property of azithromycin could justify
the continuing use of IPT in communities where the
risk of malaria is declining. The combination of artesu-
nate and piperaquine has been proposed as another
alternative for IPTp but the use of an artemisinin for
IPTp does not seem logical because of its short half-life.
A new, safe alternative to SP is needed for IPTp.
IPTp has proved to be a valuable tool for the control of
malaria in communities with medium or high levels of
transmission. However, as the incidence of malaria
declines, the benefits of IPTp may be outweighed by the
risks and costs. Below a certain level of risk, screening of
women who attend an antenatal clinic using either micro-
scopy or a rapid diagnostic test (RDT) and treatment of
just those who are positive may be a more rational and
cost effective approach than giving anti-malarials to a large
number of pregnant women who are not at risk. However,
at what level of transmission this transition should take
place is not known and needs to be investigated.
Infants
In areas of very high and perennial malaria transmission,
infants account for a substantial proportion of malaria
deaths and cases of severe disease. In such epidemiologi-
cal situations, infants are an important target group for
malaria control strategies including chemoprevention.
A study of chemoprophylaxis showed that this was an
effective way of preventing malaria and anaemia in
Tanzanian infants but there was a marked increase in
the incidence of both malaria and anaemia in the year
after chemoprophylaxis was stopped - rebound malaria
[8]. This finding led to the evaluation of a more
restricted use of chemoprevention in the first year of life
– IPT in infants (IPTi). IPTi takes advantage of the high
coverage of routine infant immunization achieved in
many malaria endemic countries to administer a course
of anti-malarial treatment at the time of vaccination.
IPTi has the major advantage that a delivery system is
already in place so that costs are largely restricted to
those of the drugs. An initial trial of IPTi in Tanzania,
in which three doses of SP were given during the first
year of life at the time of routine immunization, showed
highly encouraging results with an approximately 50%
reduction in clinical attacks of malaria and in anaemia
[14,15]. These encouraging results led to further evalua-
tion of the potential of this intervention in a number of
trials conducted across Africa, which were coordinated
by the IPTi Consortium. Combination of results from
these studies showed an approximately 30% reduction in
the incidence of clinical malaria with a variable impact
on the incidence of anaemia and hospital admissions
[16]. No significant rebound effect was noted in the
combined analysis although there was some suggestion
of a rebound in some individual trials. No impact on
mortality was detected but none of the trials was pow-
ered to detect this. IPTi with SP was well accepted by
the community, cost effective and readily implementable
[17-19]. On the basis of these findings, both an indepen-
dent evaluation of IPTi by the Institute of Medicine [20]
and a WHO technical review committee recommended
that IPTi should be implemented in communities with
medium of high levels of malaria transmission and no
significant resistance to SP.
Most studies of IPTi have used SP, which has the
major advantage that a full treatment course requires
only one dose. However, in many of the communities
where IPTi might be most effective there is a significant
level of SP resistance and an alternative drug is needed.
Mefloquine proved highly effective but, as in pregnancy,
caused a high incidence of sire effects, especially vomit-
ing [21]. Lapdap, chlorproguanil plus dapsone, was not
effective indicating the need for a long-acting drug.
Piperaquine has a long action and might be a suitable
replacement for SP, but currently is licensed only in
combination with dihydroartemisinin which is unlikely
to contribute much to IPTi as children who have clinical
malaria at the time of administration of IPTi are treated
with a full course of the recommended first-line treat-
ment for malaria. A knowledge of the pharmacokinetics
of anti-malarial drugs is essential in determining how
they can be deployed most rationally for IPTi or IPT in
older children (IPTc) [22].
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A number of studies have been undertaken recently to
model the impact of IPTi on morbidity from malaria in
different epidemiological situations [23,24] and its
potential impact on drug resistance [25].
IPTi is likely to be most effective in communities
where malaria transmission remains high and persists
throughout most of the year. As the endemicity of
malaria decreases in response to other malaria control
interventions, the proportion of cases of severe and
uncomplicated malaria in infants falls with the main
burden of the infection falling on older children, making
implementation of IPTi a less attractive prospect in
such communities.
Children
In communities where the level of malaria transmission
is only moderate and in those where malaria transmis-
sion is restricted to just a few months of the year, the
main burden of severe malaria is in older children who
would not be protected by IPTi. Thus, the impact of
administering IPT in older children has been explored,
largely in countries where malaria transmission takes
place during only a few months each year. Most of the
Sahelian and sub-Sahelian regions of Africa, which sup-
port nearly half of the population of sub-Saharan Africa,
falls into the latter category. Seasonal IPT in children
(IPTc), which involves giving a long acting anti-malarial
or anti-malarial combination at one or two monthly
intervals for a few months during the period of peak
malaria transmission, is effectively a form of targeted
chemoprophylaxis.
Studies conducted in Ghana, Mali, Senegal and The
Gambia have shown that IPTc is a highly effective inter-
vention, reducing clinical attacks of malaria by 70% -
90%, and reducing substantially all cause and malaria
specific hospital admissions [26-29]. A number of drug
combinations have been evaluated for use in IPTc.
Because the drug pressure applied by use of IPT in all
children under the age of five or ten years is greater
than that for IPTp or IPTi , it seems prudent to use a
drug combination rather than monotherapy for IPTc
and to use a different combination to the one used for
first line treatment. A number of drug combinations
have been tested for IPTc [30] with most experience
having been gained with SP + AQ. This combination
has proved highly effective in several studies although
in some, but not all, studies vomiting, probably caused
by AQ, has been an issue. This could probably be alle-
viated by preparing a more palatable formulation than
crushed tablets or by adjusting the content of AQ
tablets to make accurate dosing more readily achieved
[31]. Other drugs combinations investigated include
artesunate + SP, piperaquine + SP and artesunate +
piperaquine.
IPTc has the major disadvantage over IPTi and IPTp
that no established system for the delivery of the drug
exists in most situations where this approach to malaria
control might be applied. However, a number of studies
have shown that high levels of coverage can be achieved
using community volunteers. Implementing community
delivery programmes outside the research situation
would be a major challenge but the benefits in terms of
lives saved and episodes of malaria prevented would be
high if this could be achieved.
School children
Mass treatment programmes to control intestinal hel-
minths and schistosomiasis are in progress in a number
of malaria endemic countries and provide a vehicle
through which anti-malarial drugs could be given.
A study conducted in Uganda in which children were
given a course of SP +AQ once a term showed a sub-
stantial reduction in the incidence of anaemia in chil-
dren who received IPT and an improvement in some
aspects of their school performance [32]. Similar results
have been obtained in Mali [33]. Whether or not IPT is
an appropriate method for control of malaria in school-
children is being investigated further but the results of
these studies demonstrate that malaria may be a more
important cause of ill health and poor performance in
school children than had previously been recognized.
Mass drug administration
The term mass drug administration (MDA) has been
used to describe several different approaches to malaria
control and is thus confusing. These include administra-
tion of anti-malarials on one or more occasions to the
whole of a population at risk with the objective of redu-
cing the burden of clinical malaria (thus overlapping
with IPT) or with the objective of interrupting transmis-
sion, two very different objectives requiring different
approaches. Drugs have been given either through mass
treatment campaigns or through the fortification of salt
with anti-malarials (the Pinotti method). MDA has a
bad reputation in many quarters, including WHO, stem-
ming in part from the experience with fortified salt
which, as might have been anticipated, facilitated the
emergence and spread of resistance by exposing a large
proportion of a population at risk of malaria to sub-
therapeutic concentrations of a drug over a prolonged
period of time [34].
Several studies of MDA, sometimes combined with
vector control, were carried out in the 1950s, 1960s and
1970s and showed that MDA, especially if given repeat-
edly, could reduce parasite prevalence and the incidence
of clinical malaria substantially but that this effect was
only transitory and MDA rarely interrupts transmission
[35]. The results of a large study study conducted in
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Garki, northern Nigeria, which showed that several
rounds of MDA combined with intensive vector control
did not interrupt transmission contributed to the loss of
interest in MDA as a malaria control tool. However, res-
urrection of the prospects of malaria elimination has
reawakened interest in this approach.
Chemoprevention and elimination
Several countries, including several in Africa, have made
considerable progress in bringing malaria under control
during the past few years reawakening interest in the
possibility of local or regional elimination. It is now gen-
erally accepted that in medium or high transmission
areas, the currently deployed malaria control tools –
treatment with an artemisinin combination (ACT) and
vector control with ITNs and/or IRS - will alone be
insufficient to interrupt transmission and that an addi-
tional tool will be needed to do this. This might be a
vaccine with transmission-blocking properties or it
might be a drug given as MDA. Examples of the way in
which MDA can contribute to malaria elimination is
provided by the successful elimination programme on
the island of Aiyetun in Vanuatu [36] and recent success
in probable interruption of transmission in an area of
Cambodia [37].
If an anti-malarial drug or drug combination is used
to assist in interrupting transmission it must have good
transmission-blocking properties. Artemisinins are par-
tially effective but subjects treated with an ACT can still
transmit malaria [38] so an additional, or more effective,
gametocytocidal drug is needed if transmission is to be
completely prevented. Currently, the only licensed drug
that can completely prevent transmission of Plasmo-
dium falciparum is primaquine (Plasmodium vivax
gametocytes are killed by most anti-malarial drugs) and
there are concerns about the safety of this drug when
used for MDA in populations where glucose-6-phos-
phate-dehydrogenase (G6PD) deficiency is common.
Tafenoquine, now in clinical trials, has the advantage
over primaquine that it has a much longer period of
activity, thus providing prophylaxis as well as treatment,
but it can also cause haemolysis in G6PD positive sub-
jects. Concerns over the potential toxicity of using pri-
maquine for MDA in communities where G6PD
deficiency is common has led to investigation of the
alternative approach of mass screening and treatment of
just those who are parasite positive. However, the ability
of microscopy or current RDTs to detect very low levels
of infection, which may still be sufficient to allow trans-
mission [39], makes it uncertain whether this strategy
would work as a component of an elimination strategy
unless very sensitive molecular techniques could be
used.
Previous experience suggests that local or regional
elimination of P. vivax will be more difficult than elimi-
nation of P. falciparum, because of the persistence of
hypnozoites. If MDA is to be used as a major tool in
P. vivax elimination campaigns the drug or drug combi-
nation used must be able to kill hypnozoites and, cur-
rently, the only way that this can be done is with a
prolonged course of primaquine. A more effective drug
than primaquine, one which can ideally be given as sin-
gle dose, will be needed if drugs are to play an impor-
tant role in the elimination of P. vivax and P.ovale
infections.
Conclusions
Drugs are generally a less satisfactory way of preventing
infections than vaccines as they have to be taken regu-
larly over the period for which protection is required. In
the case of malaria this might be for life, a challenging
prospect. However, in a number of situations, anti-
malarials have an important role to play in preventing
mortality and morbidity from malaria until a time is
reached at which other more readily delivered control
measures are effective on their own. Once a high level
of control has been achieved, anti-malarials may acquire
a new role as an important contributor to local or regio-
nal elimination.
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